Abstract
Evidence suggests that regular aspirin use lowers the incidence of colorectal cancer (CRC) — a primary preventive effect. However, whether aspirin use affects cancer-specific outcomes after CRC is diagnosed (i.e., secondary prevention) is less clear. Researchers in Norway took advantage of comprehensive national data to perform this population-based observational study of secondary prevention with aspirin. Among 23,162 patients who received CRC diagnoses …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
